|
Randomized phase II trial evaluating the combination of TG4001, an HPV16 therapeutic vaccine, and avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic (R/M) HPV16-positive cervical or anogenital cancer. |
| |
|
Honoraria - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Novartis; Rakuten Medical; Roche |
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Roche; Seagen |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD |
| |
|
Consulting or Advisory Role - Eisai; Ipsen; Merck KGaA; MSD Oncology; Pfizer |
Travel, Accommodations, Expenses - Ipsen; Merck KGaA; Merck KGaA; MSD Oncology; Mundipharma; Pfizer |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Boehringer Ingelheim; Brenus Pharma; Bristol-Myers Squibb/Celgene; OSE Immunotherapeutics; Scenic Biotech; START |
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); Alligator Bioscience (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Daiichi Sankyo/UCB Japan (Inst); Debiopharm Group (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Molecular Partners (Inst); Novartis (Inst); OSE Immunotherapeutics (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Roche/Genentech (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Toray Industries (Inst); Transgene (Inst) |
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Roche |
(OPTIONAL) Uncompensated Relationships - ReACT Therapeutics |
| |
|
Honoraria - AstraZeneca/UK; GlaxoSmithKline; Pfizer |
Travel, Accommodations, Expenses - GlaxoSmithKline; Merck Sharp & Dohme; pharma& |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - BMS; Merck; Merus; MSD |
Travel, Accommodations, Expenses - BMS; Merck |
| |
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Tesaro |
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Roche/Genentech |
Research Funding - Tesaro |
Travel, Accommodations, Expenses - GlaxoSmithKline; MSD Oncology; Novartis; Roche/Genentech; Tesaro |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca Spain; Eisai |
Travel, Accommodations, Expenses - AstraZeneca Spain; PharmaMar |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); MSD Oncology; MSD Oncology (Inst); MSD Oncology (Inst); Stada KSA |
Research Funding - Onxeo (Inst); PharmaMar (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Mundipharma |
Other Relationship - PharmaMar |
| |
|
Consulting or Advisory Role - Biomunex |
Research Funding - Biomunex (Inst); Transgene (Inst) |
Patents, Royalties, Other Intellectual Property - Biolegend royalties for 3C10 antibody (Inst) |
| |
|
Employment - Bayer; Transgene |
|
| |
|
|
Stock and Other Ownership Interests - Transgene |
| |
|
Employment - Hookipa Pharma; Transgene |
| |
|
|
Stock and Other Ownership Interests - Transgene |
| |
|
|
Stock and Other Ownership Interests - Transgene |
| |
|
|
Stock and Other Ownership Interests - Transgene |
| |
|
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst) |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); MSD Oncology (Inst); Transgene (Inst) |